Morgan Stanley Viridian Therapeutics, Inc.\De Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Morgan Stanley holds 1,009,879 shares of VRDN stock, worth $18.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,009,879

Previous 320,570 215.03%

Holding current value

$18.7 Million

Previous $4.17 Million 450.94%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$12.16 - $23.33 $8.38 Million - $16.1 Million	689,309 Added 215.03%	1,009,879 $23 Million
Q2 2024 Oct 17, 2024	SELL	$11.6 - $17.26 $2.81 Million - $4.18 Million	-241,971 Reduced 43.01%	320,570 $4.17 Million
Q2 2024 Aug 14, 2024	SELL	$11.6 - $17.26 $2.81 Million - $4.18 Million	-241,971 Reduced 43.01%	320,570 $4.17 Million
Q1 2024 Oct 17, 2024	BUY	$17.09 - $23.82 $4.14 Million - $5.76 Million	241,971 Added 75.48%	562,541 $9.85 Million
Q1 2024 Aug 16, 2024	BUY	$17.09 - $23.82 $643,267 - $896,584	37,640 Added 7.17%	562,541 $9.85 Million
Q1 2024 May 15, 2024	BUY	$17.09 - $23.82 $643,267 - $896,584	37,640 Added 7.17%	562,541 $9.85 Million
Q4 2023 Aug 16, 2024	BUY	$11.12 - $22.5 $2.27 Million - $4.6 Million	204,331 Added 63.74%	524,901 $11.4 Million
Q4 2023 Feb 13, 2024	BUY	$11.12 - $22.5 $2.13 Million - $4.3 Million	191,178 Added 57.29%	524,901 $11.4 Million
Q3 2023 Nov 15, 2023	BUY	$15.16 - $24.7 $4 Million - $6.52 Million	264,044 Added 378.94%	333,723 $5.12 Million
Q2 2023 Aug 14, 2023	SELL	$22.57 - $29.67 $8.2 Million - $10.8 Million	-363,455 Reduced 83.91%	69,679 $1.66 Million
Q1 2023 May 15, 2023	BUY	$25.04 - $37.6 $2.45 Million - $3.68 Million	97,832 Added 29.18%	433,134 $11 Million
Q4 2022 Feb 14, 2023	BUY	$18.78 - $29.74 $3.2 Million - $5.07 Million	170,544 Added 103.51%	335,302 $9.79 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $1.47 Million - $3.5 Million	137,175 Added 497.32%	164,758 $3.38 Million
Q2 2022 Oct 27, 2022	SELL	$9.55 - $19.0 $70,154 - $139,574	-7,346 Reduced 21.03%	27,583 $319,000
Q2 2022 Aug 15, 2022	SELL	$9.55 - $19.0 $70,154 - $139,574	-7,346 Reduced 21.03%	27,583 $319,000
Q1 2022 Oct 27, 2022	BUY	$16.79 - $20.88 $123,339 - $153,384	7,346 Added 26.63%	34,929 $646,000
Q1 2022 May 13, 2022	BUY	$16.79 - $20.88 $356,518 - $443,365	21,234 Added 155.05%	34,929 $646,000
Q4 2021 Feb 14, 2022	BUY	$15.65 - $21.5 $59,047 - $81,119	3,773 Added 38.03%	13,695 $271,000
Q3 2021 Nov 15, 2021	BUY	$10.69 - $18.2 $106,066 - $180,580	9,922 New	9,922 $163,000

Others Institutions Holding VRDN

# of Institutions

180

Shares Held

76.7M

Call Options Held

581K

Put Options Held

439K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $739M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account